Figure 4 from A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)

Progression-free survival (PFS) in solid tumor malignancies other than ccRCC (A) or in ccRCC (B). Dotted lines represent a 95% confidence interval.